This compound is a conjugated form of the antimitotic agent monomethyl auristatin E (MMAE), linked through a maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate (mc-vc-PAB) spacer. It is primarily used as an intermediate in the manufacturing of antibody-drug conjugates (ADCs), enabling the stable attachment of the cytotoxic payload to targeting antibodies.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 646502-53-6
(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
pharmaceutical raw material
Monomethyl auristatin F
pharmaceutical intermediate
VC-PAB-MMAE
pharmaceutical intermediate
N-(2-Bromo-4,5-difluorophenyl)acetamide
pharmaceutical intermediate
Gabapentin-lactam
pharmaceutical intermediate
1-Bromo-2-methoxyethane
pharmaceutical intermediate
L-Phenylglycinamide
pharmaceutical intermediate
Monomethyl auristatin E
pharmaceutical intermediate
(2S)-N-[(2S)-1-[[(3R,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
DASWEROEPLKSEI-AWNAIHLBSA-N
CC[C@H](C)C([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC